Index S&P 500
P/E 37.40
EPS (ttm) 6.02
Insider Own 0.28%
Shs Outstand 287.14M
Perf Week -1.93%
Market Cap 64.64B
Forward P/E 14.38
EPS next Y 15.65
Insider Trans -1.51%
Shs Float 286.34M
Perf Month -4.73%
Income 1.75B
PEG 4.16
EPS next Q 3.30
Inst Own 92.45%
Short Float 0.94%
Perf Quarter -2.63%
Sales 20.64B
P/S 3.13
EPS this Y 9.78%
Inst Trans -0.98%
Short Ratio 1.28
Perf Half Y -3.80%
Book/sh 87.78
P/B 2.56
EPS next Y 8.51%
ROA 3.27%
Short Interest 2.70M
Perf Year -5.65%
Cash/sh 2.89
P/C 77.88
EPS next 5Y 9.00%
ROE 6.92%
52W Range 218.75 - 251.99
Perf YTD -0.77%
Dividend Est. 3.88 (1.72%)
P/FCF 22.02
EPS past 5Y 8.27%
ROI 4.10%
52W High -10.66%
Beta 0.35
Dividend TTM 3.89 (1.73%)
Quick Ratio 0.63
Sales past 5Y 4.72%
Gross Margin 45.35%
52W Low 2.92%
ATR (14) 4.84
Dividend Ex-Date Mar 10, 2025
Current Ratio 1.13
EPS Y/Y TTM 42.05%
Oper. Margin 14.13%
RSI (14) 36.17
Volatility 1.32% 1.87%
Employees 74000
Debt/Eq 0.74
Sales Y/Y TTM 5.89%
Profit Margin 8.47%
Recom 1.58
Target Price 271.00
Option/Short Yes / Yes
LT Debt/Eq 0.69
EPS Q/Q 8.20%
Payout 64.86%
Rel Volume 0.63
Prev Close 224.80
Sales Surprise 1.33%
EPS Surprise 15.18%
Sales Q/Q 9.82%
Earnings Feb 06 BMO
Avg Volume 2.11M
Price 225.13
SMA20 -5.31%
SMA50 -2.90%
SMA200 -3.63%
Trades
Volume 1,335,209
Change 0.15%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-01-24 Upgrade
Citigroup
Neutral → Buy
$255 → $275
May-30-24 Initiated
Goldman
Buy
$274
Jul-24-23 Upgrade
Raymond James
Mkt Perform → Outperform
$305
May-30-23 Resumed
Morgan Stanley
Overweight
$295
May-05-23 Upgrade
Piper Sandler
Neutral → Overweight
$260 → $290
Apr-12-23 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$304
Jan-03-23 Upgrade
BofA Securities
Neutral → Buy
$250 → $290
Dec-12-22 Upgrade
Citigroup
Sell → Neutral
$221 → $250
Jul-11-22 Downgrade
Citigroup
Neutral → Sell
$265 → $235
Jun-24-22 Upgrade
Wells Fargo
Equal Weight → Overweight
$275
Mar-18-22 Resumed
Raymond James
Mkt Perform
Mar-02-22 Resumed
BofA Securities
Neutral
$290
Dec-08-21 Downgrade
Piper Sandler
Overweight → Neutral
$285 → $260
Aug-06-21 Downgrade
JP Morgan
Overweight → Neutral
$265
May-25-21 Initiated
Barclays
Equal Weight
$270
Dec-15-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$297
Dec-15-20 Downgrade
Wells Fargo
Overweight → Equal Weight
$265
Jul-09-20 Upgrade
Barclays
Equal Weight → Overweight
$300
Jun-01-20 Resumed
Goldman
Buy
$278
Mar-05-20 Initiated
Citigroup
Neutral
$260
Show Previous Ratings
Feb-18-25 08:30AM
Feb-13-25 04:15PM
Feb-12-25 09:45AM
Feb-07-25 12:43PM
09:30AM
02:07AM
Loading…
02:07AM
12:08AM
(Thomson Reuters StreetEvents)
Feb-06-25 01:50PM
12:31PM
10:24AM
Feb-05-25 06:30PM
05:55PM
05:02PM
(The Wall Street Journal)
04:49PM
(Associated Press Finance)
04:30PM
04:30PM
Loading…
04:30PM
08:07AM
Feb-03-25 09:16AM
09:09AM
Jan-30-25 10:01AM
Jan-28-25 04:15PM
05:30AM
(The Wall Street Journal)
Jan-24-25 12:27PM
Jan-23-25 07:15AM
Jan-22-25 11:07AM
06:50AM
Jan-21-25 05:22PM
(The Wall Street Journal)
Jan-16-25 04:15PM
Jan-15-25 08:56AM
06:50AM
06:50AM
Loading…
06:50AM
Jan-14-25 02:06PM
Jan-13-25 06:50AM
Jan-10-25 09:44AM
06:50AM
Jan-09-25 09:45AM
06:50AM
Jan-07-25 04:15PM
12:10PM
Jan-03-25 09:40AM
Dec-20-24 09:45AM
Dec-18-24 09:40AM
06:18AM
Dec-17-24 09:50AM
06:50AM
Dec-16-24 05:52PM
04:46PM
04:32PM
08:08AM
Dec-14-24 06:19AM
12:10AM
Dec-05-24 04:05PM
Dec-02-24 02:21PM
Nov-26-24 01:15PM
Nov-20-24 02:15PM
Nov-19-24 04:15PM
Nov-12-24 01:02PM
Nov-11-24 09:40AM
Nov-08-24 02:07AM
Nov-07-24 11:56PM
(Thomson Reuters StreetEvents) -5.39%
01:18PM
12:45PM
10:13AM
09:30AM
07:45AM
06:52AM
(Associated Press Finance)
06:30AM
06:25AM
Nov-04-24 09:16AM
Nov-03-24 01:37PM
Oct-31-24 10:01AM
Oct-30-24 09:40AM
06:50AM
06:05AM
Oct-29-24 09:45AM
06:50AM
Oct-25-24 06:53AM
Oct-22-24 12:45PM
Oct-15-24 05:07AM
Oct-14-24 09:40AM
06:45AM
Oct-11-24 12:10PM
09:45AM
Oct-10-24 07:21PM
04:15PM
Oct-07-24 09:50AM
Oct-03-24 05:05PM
Oct-02-24 05:00PM
08:40AM
Sep-26-24 06:50AM
Sep-25-24 04:05PM
Sep-18-24 06:50AM
Sep-10-24 09:40AM
Sep-09-24 09:45AM
Sep-04-24 05:32AM
Sep-03-24 04:30PM
04:30PM
Aug-23-24 09:45AM
Aug-22-24 01:00PM
09:40AM
Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SCOTT BERTRAM L Director Feb 12 '25 Sale 227.99 700 159,593 36,033 Feb 12 04:44 PM BERTRAM SCOTT Director Feb 12 '25 Proposed Sale 227.99 700 159,593 Feb 12 04:12 PM Henderson Jeffrey William Director Feb 10 '25 Buy 233.62 1,500 350,430 8,015 Feb 10 05:03 PM Shan David EVP and Chief ISC Officer Jan 21 '25 Sale 240.00 500 120,000 5,741 Jan 22 09:19 AM Neal Shana Carol EVP and Chief People Officer Jan 21 '25 Sale 240.00 787 188,880 15,414 Jan 22 09:18 AM SHANA NEAL Officer Jan 21 '25 Proposed Sale 237.38 787 186,818 Jan 21 04:21 PM DAVID SHAN Officer Jan 21 '25 Proposed Sale 237.38 500 118,690 Jan 21 01:47 PM Garrison Michael David EVP & President, Medical Jan 17 '25 Sale 236.51 597 141,196 5,544 Jan 21 08:21 AM MICHAEL GARRISON Officer Jan 17 '25 Proposed Sale 236.30 597 141,071 Jan 17 04:20 PM Neal Shana Carol EVP and Chief People Officer Nov 21 '24 Option Exercise 0.00 111 0 17,021 Jan 10 07:11 AM Neal Shana Carol EVP and Chief People Officer Jan 07 '25 Sale 235.00 788 185,180 16,201 Jan 10 07:11 AM SHANA NEAL Officer Jan 07 '25 Proposed Sale 230.70 788 181,792 Jan 07 04:19 PM Garrison Michael David EVP & President, Medical Dec 19 '24 Sale 223.33 2,838 633,811 6,141 Dec 20 10:18 AM MICHAEL GARRISON Officer Dec 19 '24 Proposed Sale 224.09 2,838 635,967 Dec 19 04:20 PM Goette Roland EVP and President, EMEA Dec 06 '24 Option Exercise 157.30 13,334 2,097,403 28,828 Dec 10 08:23 PM Goette Roland EVP and President, EMEA Dec 06 '24 Sale 221.01 4,483 990,788 24,345 Dec 10 08:23 PM Goette Roland EVP and President, EMEA Dec 09 '24 Sale 219.03 638 139,741 14,217 Dec 10 08:23 PM Neal Shana Carol EVP and Chief People Officer Dec 06 '24 Sale 220.49 1,000 220,490 16,989 Dec 10 08:17 PM ROLAND GOETTE Officer Dec 09 '24 Proposed Sale 220.02 638 140,373 Dec 09 04:47 PM Shan David EVP and Chief ISC Officer Dec 05 '24 Sale 220.25 1,500 330,375 6,285 Dec 06 04:55 PM ROLAND GOETTE Officer Dec 06 '24 Proposed Sale 222.24 4,483 996,302 Dec 06 04:31 PM SHANA NEAL Officer Dec 06 '24 Proposed Sale 222.24 1,000 222,240 Dec 06 04:31 PM DAVID SHAN Officer Dec 05 '24 Proposed Sale 221.43 1,500 332,145 Dec 05 04:42 PM BURZIK CATHERINE M Director Sep 16 '24 Proposed Sale 235.78 400 94,312 Sep 16 11:52 AM Goette Roland EVP and President EMEA Aug 14 '24 Option Exercise 132.54 5,295 701,799 16,603 Aug 15 01:47 PM Spoerel Thomas J SVP,Controller&Chief Acct Off Jun 10 '24 Sale 239.31 300 71,793 1,976 Jun 11 01:45 PM Goette Roland EVP and President EMEA May 15 '24 Sale 236.73 3,300 781,224 11,308 May 16 07:54 PM Goette Roland EVP and President EMEA May 13 '24 Sale 236.70 3,300 781,121 14,608 May 15 02:44 PM Garrison Michael David EVP & President Medical Apr 30 '24 Sale 232.81 1,715 399,269 5,381 May 01 12:59 PM Spoerel Thomas J SVP,Controller&Chief Acct Off Mar 14 '24 Sale 238.29 282 67,198 2,276 Mar 15 02:19 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite